Those we love don't go away They walk beside us every moment

1

Prof. Ola Nabih Abdel FatahAssistant Professor of Clinical Oncology Assiut University1974 - 2020

Prof. Ola Nabih, a rising star in the oncology field, served as an Assistant professor in the Department of Clinical Oncology at Assiut University and the General Secretary of the Clinical Oncology Department annual conference for 11 consecutive years.

Dr. Ola was a faithful friend and a great physician. Time will not erase her work and the lives she has positively affected. We will be forever grateful for her tremendous efforts and time.

In her memory, we would like to announce the annual Prof. Ola Nabih's Award, Supported by the Assiut Clinical Oncology Department, for the best young oncologist oral poster presenter.

Those we love don't go away ... They walk beside us every moment

Welcome MessageDear Colleagues and Friends, It is a great pleasure and honor to extend you a warm invitation to attend the 12th Annual international conference of clinical oncology department, Assuit university, That will be held on February 24- 26, 2021 in Jolie Ville Hotel, Luxor, EgyptThis conference will be done in collaboration with Arab Medical Association Against Cancer(AMAAC), Egyptian Cancer Society (ECS), Kasr EL-Aini School of Oncology (KASO), EgyptianHematology Oncology Group (EHOG) and, the Egyptian Society for Liver Cancer (ESLC).Our goal is to bring together national and International expert oncologists to improve the knowledge about the new trends and challenges in management of various cancers and to build an international scientific collaborative network.We welcome your participation in this educational program and we hope you will enjoy the conference and the beautiful culture and architectures of Luxor

Prof. Samir Shehata Mohamed

SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر

Clinical Oncology Department Assiut University

12th

2

Conference Moderators

Head of Organizing Committee

Head of Scientific Committee

Honorary PresidentsProf. Sami ElKhatib

President of AMAAC

Prof. Hussien KhaledPresident of EHOG

Prof. Hamdy Abdel AzimPresident of KASO

Prof. Mostafa ElSerafiPresident of Egyptian Cancer Society

Prof. Ashraf OmarPresident of ESLC

Prof. Amina Mohamed MostafaProf. of Clinical Oncology

Prof. Samia Abdel KareemProf. of Clinical Oncology

Prof. Mohamed MekkawyProf. of Clinical Oncology

Prof. Hatem Abo ElkassemDean of NCI

Under the Patronage of

Prof. Shehata GhareebVice President for Education

Student Affairs

Prof. Maha Kamel GhanemVice President for EnvironmentalAffairs and Community Service

Prof. Tarek El GammalPresident of Assuit University

Prof. Ahmed El MenshawyVice President for Graduate

Studies and Research

Conference President Prof. Samir Shehata Mohamed

Head of Clinical Oncology and Nuclear Medicine Department

Prof. Maha SalahAss. Prof. of Clinical Oncology

Prof. Reham Abdel-WahabAss. Prof. of Clinical Oncology

Prof. Hanan Gamal Eldin Prof. of Clinical Oncology

Prof. Hoda Hassan EssaProf. of Clinical Oncology

Prof. Taha ZakiProf. of Clinical Oncology

Prof. Samy El-GezawyProf. of Clinical Oncology

Dean of Faculty of MedicineProf. Alaa Attia

3

Members of Scientific Committee

Members of Organizing Committee:

Abbas OmarAbdel Aziz BelalAbdel Salam AttiaAbeer FayekAdel ElSayesAhmed AllamAhmed AlshehryAhmed ElDorryAhmed ElZawawyAhmed GamalAhmed Saad EldinAlaa ElhaddadAlaa KandilAly Shams EldinAmal EmamAmal RyanAmany SaberAmen Hamdy ZakiAmeny HelalAshraf BarakatAshraf ElghandourAshraf FarragAsmaa Abdel TawabAyat MorsyAyman Abdel SameeaDalia Abd ElmoetyDoaa Aly GamalEhab KhalilEhab MostafaEhsan ElghoniemyEmad DawoudEmad EhabEmad HamadaFady GearaFouad Abo TalebGamal ElHosienyHamdy Abdel AzimHamdy ElzawamHamed Mostafa

Hanaa KohilHanan HamedHasham Abdel ElSemeeaHassan GaafarHala elshenshawyHatem AmeenHazem ElakadHeba ElzawahryHesham ElGhazalyHesham ElwakilHesham HamzaHesham MostafaHesham TawfeekHoda Abdel BakyHoda HassanHosna MostafaHossam KamelHussin RabieeIbrahim AlSheneberIbrahim AwadIbtesam Saad EldeenInas Abdel HalimKamal ElghamrawyKhaled Abdel KareemKhaled KamalLaila MoussaLamia MahmoudLobna Ezz ElarabLobna SedkyMagda AllamMagda MostafaMagdy SaberMaha ElZafaranyMahmoud EltohamyMahmoud EmetienyMahmoud SalahManal ElSouradyManal MoawadMarwa Ismail

Marwan GhosnMedhat ElsebaieMervat ElNaggarMervat MattarMervat OmerMohamed AbdallahMohamed Abdel HakimMohamed Abdel KaderMohamed Abdel MoatyMohamed Aboel FotouhMohamed AlaaMohamed AlbassuniMohamed AzazziMohamed ElsherbenyMohamed FaroukMohamed Hosam KhaledMohamed KhalafMohamed LotayefMohamed MostafaMohamed MoussaMohamed Saad ZaghloulMohamed SalahMohamed SolimanMohammed HosnyMohsen BarsoomMohsen MokhtarMona Abo El AninMonier Abo ElelaMostafa Abdel WanisMostafa ElSharkawyNabil MobarakNadia Abdel MonemNadia ElDeebNadia MahhanyNagi ElSaghirNaser Abdel BaryNasr EllahloubiNeemat KassemNier ElGhamry

Noha AdlyOla KhorshidOm Elkhair Abo ElkairOmar FahmyOmar ZakiOsama ElmaltOthman MansourRabab GhafaarRafaat Abdel FattahRehab FaroukSaied NewaemSalah Abdel MoniemSalah El MesedySamar ElmorshedySameh ShamaaSamy ErfanSamy ElbadawySayed MostafaSeham ElhagrasyShawky BaserbashyShawky ElHadadSherif AbdelwahabSoher lsmailSomia EzzatTamer RefaatTarek ElgoharyTarek HashemTarek SalahTarek ShowmanWafaa ElmetnawyWafaa MohamedWalid ElNahhasWalid DiabYasser Abdel GawadYasser Abdel KaderYasser KhafagaYosra DorghamYosri RostumYosri Wassef

Ereny SamuelAhmed AshrafDina Barakat

Nada HasanHeba Bakri Heba Sheha

Mariam MohsenDoaa Abd El-AleemYousra FarghalyDonia Hussien

Ahmed GamalSohiala EsamRehab OsamaGehad ahmed



12th

4

Registration

GIT (I) Session

15:00- 15:30 Recent advances in management of GEJ locally advanced and metastatic setting

Prof. Salem Eid Prof. Mohamed Farouk 15:30- 15:50 Advanced biliary cancer : How to deal ? (Virtual)

Prof. Shawki Bazarbashi (KSA)

15:50- 16:10 Surgical management of pancreatic cancer Prof. Ibrahim Al Sheneber (KSA) (Virtual)

16:10- 16:30 Immunotherapy in HCC Prof. Amr Shafik (Virtual)

16:30- 16:50 Total neoadjuvant strategies for colon and rectal cancer: what’s new in oncology.

Prof. Ahmed Seleem

16:50- 17:00 Round Table Discussion GIT (1)

24th

FEBRUARY

WEDNESDAY

24th

FEBRUARY

WEDNESDAY

12:0015:00

15:0017:00

Hall (A)

Chairpersons (Alphabetically):

Prof. Abdelaziz BelalProf. Abdelsalam Attia Prof. Amany SaberProf. Ashraf Barakat

Prof. Emad Shash Prof. Hesham TawfikProf. Inas AbdelhalimProf. Mohamed Abo ElFotouh

ModeratorsProf. Abbas OmarProf. Hesham Elghazaly

5

Management of first line mCRC

24th

FEBRUARY

WEDNESDAY

17:0017:30

Chairperson : Prof. Emad HamadaSpeaker: Prof. Mohamed Abdallah

Hall (A)

(Amgen Symposim)

Trifluridine/Tipiracil; Fingerprint in GI oncology

24th

FEBRUARY

WEDNESDAY

17:3018:00

Chairperson : Prof. Samir ShehataSpeaker: Prof. Mohamed Abdallah

Hall (A)

(Servier Symposim)

GIT (II) Session

24th

FEBRUARY

WEDNESDAY

18:0019:20

Hall (A)

18:00- 18:20 Adjuvant treatment in CRC (Virtual) Prof. Sahin Lacin (USA)

18:20- 18:40 Met. CRC with limited liver mets (Virtual) Prof . Alexandra Stewart (UK)

18:40- 19:10 Personalized approach in m. CRC Prof. Mohamed Abdallah

19:10-19:20 Round Table Discussion (GIT II)


Prof. Hussien Fakhry Prof. Hussein MekkyProf. Mohamed Basiouny Prof. Mohamed GamilProf. Mostafa Abdel Wanis

Prof. Nadia Abdel MoniemProf. Samy RamzyProf. Seham ELhagrasy Prof. Wafaa Elmitnawy

ModeratorsProf. Magda AllamProf. Nehal El-MashadProf. Yosry Rostom



12th

6

GIST A real precision drived tumor

24th

FEBRUARY

WEDNESDAY

19:2019:50

Speaker: Prof. Mohsen Mokhtar

Hall (A)

(Bayer Symposium)

Treatment sequence optimization for mCRC patients + Case Discussion 24th

FEBRUARY

WEDNESDAY

19:50 20:20

Speaker: Prof. Tarek HashemCase Discussion : Prof. Hossam Elashtokhy

Hall (A)

(Merck Symposium)

Enhancing Patients’ Choices with Biosimilars

24th

FEBRUARY

WEDNESDAY

20:20 20.50

Speaker: Prof. Mohsen Mokhtar

Hall (A)

(Sandoz Symposium)

7

GU Session

15:00- 15:20 Chemotherapy, immunotherapy or combinations: What is the best option in the face of new evidence in advanced UB ? Prof. Ahmed Saadeddin (KSA) (Virtual)

15:20- 15:40 The Future Is Now?: Targeted Therapy in Endometrial Cancer Prof. Hassan Gaffar (UAE) (Virtual)

15:40- 16:00 Sentinel lymph node in endometrial cancer

Prof. Gamal Emera

16:00- 16:20 Surgery in cancer patients in the era of covid 19 Prof. Hesham Abu Taleb

16:20- 16:40 Overview of Immunotherapeutic Approaches in Ovarian Cancer Prof. Rami Ghali (Virtual)

16:40- 17:00 First-Line PARP inhibition in ovarian cancer : The success storyProf. Sami El Gizawy

17:00- 17:20 How to sequence ttt in M. RCCProf. Emad Hamada

24th

FEBRUARY

WEDNESDAY

15:0019:00

Hall (B)


Prof. Hazem ElAKaadProf. Khaled KamalProf. Osama ElMaltProf. Osman Mansour

Prof. Rasha Hagag Prof. Saied Noeiam Prof. Tarek Hashem Prof. Wafaa Ashour

ModeratorsProf. Ibtesam Saad EldinProf. Taha Zaki



12th

8

Round Table Discussion (GU)24th

FEBRUARY

WEDNESDAY

18:4019:00

Hall (B)

A new Paradigm in management of mHSPC patients 24th

FEBRUARY

WEDNESDAY

18:1018:40

(Janssen Symposium)

Hall (B)

Speaker: Prof. Mohamed Abdallah

State of Art in Management of Metastatic Prostate Cancer 24th

FEBRUARY

WEDNESDAY

17:5018:10

Chairperson : Prof. Samir ShehataSpeaker: Prof. Emad Hamada

(Sanofi Symposium)

Hall (B)

Role of Fulvestrant in endocrine receptors +ve breast cancer patients 24th

FEBRUARY

WEDNESDAY

19:3020:00

Speaker: Prof. Hassan Metwally

(Sandoz Symposium)

Hall (B)

Chemotherapy Optimal Management of HER2 Negative MBC 24th

FEBRUARY

WEDNESDAY

19:00 19:30

Speaker: Prof. Hamdy Abdel Azim

(New Bridge Symposium)

Hall (B)

Personalized approach in the management of CRPC patients 24th

FEBRUARY

WEDNESDAY

17:2017:50

Moderator : Prof. Hesham TawfikSpeaker: Prof. Salem Eid

(Astellas Symposium)

Hall (B)

9

25th

FEBRUARY

THURSDAY

Breast (I) Session

10:00- 11:30 Challenging the standards in ttt of EBC : • CDk4/6 inhibitors in Adjuvant setting • Immunotherapy therapy in neoadjuvant NATNBC • Response driven ttt of HER2 +ve EBC

13:00- 13:20 ABC guidelines , background and updates in metastatic breast cancer Prof. Nagi Elsaghir (Lebanon) (Virtual)

13:20- 13:50 Breast cancer in young women from biology to treatment and survivorship. Prof. Matteo Lambertini (Italy) (Virtual)

13:50- 14:00 Round table discussion breast 1

10:00 14:00

Hall (A)


Prof. Ashraf SelimProf. Elia AnisProf. Emad Khallaf

Prof. Samir ShehataProf. Sherif NaguibDr. Loay Kassem

Moderator & SpeakerProf. Hamdy Abdel Azim

25th

FEBRUARY

THURSDAY

Hall (A)

Treatment optimization of HER2+ eBC: The Science and Art

11:3013:00

Panelists (Alphabetically):Prof. Ahmed Abd ElazizProf. Alaa Kandil

Prof. Ashraf SelimProf. Dorria Salem

Prof. Omar ZakaryaProf. Sherif NaguibDr Loay Kassem

Roche Symposium




12th

10

14:00- 14:20 Novel therapies for refractory and relapsed HER2 + ve MBCProf. Marwan Ghosn (Virtual)

14:20- 14:40 What is beyond CD4/6 inhibitors in HR+ve Her2-ve breast cancer Prof. Alaa Kandil

14:40- 15:00 Optimal use of PARPI to improve breast outcomesProf. Marwa Ismail

15:00- 16:00 Lunch Break16:00- 16:20 Immunotherapy in m .TNBC

Prof. Nasr Allahloubi

25th

FEBRUARY

THURSDAY

Session Breast (II)14:00 16:00

Hall (A)


Prof. Ahmed HassanProf. Hassan Metwally Prof. Hesham HamzaProf. Lobna Sedky

Prof. Mohamed HassProf. Nabil MubarkProf. Tarek ShomanProf. Yasser El KarmProf. Yousry Wassef

ModeratorsProf. Sherif Abdel WahabProf. Waleed Arafat

25th

FEBRUARY

THURSDAY

Hall (A)

Biosimilars in Breast Cancer16:20 16:50

Chairperson : Prof. Emad HamadaSpeaker: Prof. Hamdy Abdel Azim

(Amgen Symposium)

25th

FEBRUARY

THURSDAY

Hall (A)

Oral chemotherapy in times of Covid-1916:50 17:20

Speaker: Prof. Emad Hamada

(Pierre Fabre Symposium)

11

25th

FEBRUARY

THURSDAY

Lung Session

17:20- 17:40 Adjuvant treatment for EGFR positive NSCLCProf. Mahmoud Abdelsalam (Canada) (Virtual)

17:40- 18:00 Emerging strategies in EGFR mutant metastatic NSCLC treatment Prof. Yasser Abdelkader

18:00- 18:20 ALK inhibitors sequencing in lung cancerProf. Rabab Gaafar

18:20- 18:40 SCLC in the era of immunotherapy .Prof. Ahmed Magdi

18:40- 19:00 Mesothelioma updated management Prof. Nafisa Abd ElHafiz (KSA) (Virtual)

19:00- 19:15 Round Table Discussion lung

17:20 19:15

Hall (A)


Prof. Amany HelalProf. Hala EL ShenshawyProf. Hanaa Kohil

Prof. Mohamed Abd ElkaderProf. Mohamed MekkawyProf. Nasr Abd El BaryProf. Olaa Khorshid

ModeratorsProf. Lobna Ezz ElArabProf. Maha Kamel Ghanem Prof. Samir Shehata



12th

12

ChairpersonsProf.Hesham Tawfik Prof. Tarek Hashem

ChairpersonsProf. Hesham Tawfik Prof. Tarek Hashem

25th

FEBRUARY

THURSDAY

25th

FEBRUARY

THURSDAY

Hall (A)

Hall (A)

5 Years Survival for Young women

From theory to practice: case presentation

19:1519:35

19:3519:55

(Novartis Symposium)


Speaker: Prof.Heba El Zawahry

Speaker:Dr. Nawal El Tohamy

25th

FEBRUARY

THURSDAY

Opening ceremony20:0021:00

Hall (A)

13Break 12:00-12:15

25th

FEBRUARY

THURSDAY

Hematology session10:0015:00

Hall (B)

Chairpersons and panelistsProf. Adel Abdel RehimProf. Mahmoud Salah Prof. Mohamed Abdel Moaty

Prof. Mohamed MoussaProf. Osama HassanProf. Sameh Shamaa

25th

FEBRUARY

THURSDAY

25th

FEBRUARY

THURSDAY

25th

FEBRUARY

THURSDAY

25th

FEBRUARY

THURSDAY

The Role of immunotherapy in the fourth line treatment of cHL

Multiple myeloma from Clinical trials to Real-World evidence

Relapsed /Refractory Multiple Myeloma

Round Table Discussion (MM)

10:0010:30

10:3011:00

11:0011:30

11:3012:00

Hall (B)

Hall (B)

Hall (B)

Hall (B)

(MSD Symposium)

(Takeda Symposium)

(Amgen Symposium)

Speaker: Prof. Rafaat Abdel Fattah

Speaker: Prof. Mohamed Moussa

Speaker: Prof. Mohamed Abdel Moaty



12th

14

25th

FEBRUARY

THURSDAY

Better future for Lymphoma Patients : Mabthera SC in Action

14:3015:00

25th

FEBRUARY

THURSDAY

Round Table Discussion (CLL)13:1514:30

Hall (B)

Hall (B)

25th

FEBRUARY

THURSDAY

Redefining Expectations in AML12:1512:30

Hall (B)

(Abbvie Symposium)Speaker: Prof. Gamal Fathy

25th

FEBRUARY

THURSDAY

Moving to a new era in CLL12:3012:45

Hall (B)

(Abbvie Symposium)Speaker: Prof. Mervat Mattar

25th

FEBRUARY

THURSDAY

Update in frontline therapy in CLL12:4513:15

Hall (B)

(Janssen Symposium)

(Roche Symposium)

Speaker: Prof. Rafaat Abdel Fattah

Lunch break 15:00-16:00

25th

FEBRUARY

THURSDAY

Hematology session

Hall (B)

Chairpersons and panelistsProf. Gamal Fathy Prof. George Bahig

Prof. Mervat MattarProf. Mohamed Azazi

Prof. Mohamed KhalafProf. Sherief Mahmoud

Speaker: Prof. Mohamed Abdel Moaty

15

25th

FEBRUARY

THURSDAY

Head and Neck Session16:0017:30

Hall (B)

16:00- 16:20 Prevention and screening in H&N cancer Prof. Abhishek Shankar (India) (Virtual)

16:20- 16:40 Coupling and decoupling of tumer immunity from auto immunity induced by check point inhibi-tors .

Prof . Adi Diab (USA) (Virtual)

16:40- 17:00 Recent updates in Immune therapy in H&NProf. Mohsen Mokhtar

17:00- 17:20 Gamma Knife radiosurgery for pituitary adenomaProf. Khaled Abdel Karim

17:20- 17:30 Round table discussion H&N


Prof. Hesham MostafaProf. Medhat ElSebaieProf. Mervat ElNagarProf. Mostafa Hashem

Prof. Rafaat Aly Saber Prof. Sayed Mostafa Prof. Yosry Goda

ModeratorsProf. Hoda Abdel BakyProf. Maha ElNagar



12th

16

25th

FEBRUARY

THURSDAY

Evolving role of PI3k inhibitors in management of HR+ve HER2-ve ABC

19:00 19:20

Hall (B)

25th

FEBRUARY

THURSDAY

Changing land scape of 1st line NSCLC management

18:0018:30

Hall (B)

(BMS Symposium)


25th

FEBRUARY

THURSDAY

Paradigm shift of 1st line treatment in HNSCC

17:3018:00

Hall (B)

(MSD Symposium)

Speaker: Prof .Mohamed Abdallah


25th

FEBRUARY

THURSDAY

Ibrance: Translating evidence to real world practice

18:30 19:00

Hall (B)

(Pfizer Symposium)

Speaker: Prof. Alaa Kandil

Chairpersons : Prof.Yasser Abdel Kadder Speaker: Prof. Alaa Kandil

17

25th

FEBRUARY

THURSDAY

Opening ceremony20:0021:00

Hall (A)

Counselor. Mostafa Alham

Prof. Tarek El Gammal

Prof. Ahmed El Menshawy

Prof. Shehata Ghareeb

Prof. Maha Kamel Ghanem

Prof. Alaa Attia

Prof. Hatem Abo ElKassem

Prof Youssef Salah

Prof Amany Omar

Prof Saad Zaki

Prof. Sami ElKhatib

Prof. Hussien Khaled

Prof. Hamdy Abdel Azim

Prof. Mostafa ElSerafy

Prof. Ashraf Omar

Prof. Samir Shehata

Luxor Governor

President of Assuit University

Vice President for Graduate Studies and Research

Vice President for Education Student Affairs

Vice President for Environmental Affairs and Commu-nity Service

Dean of Faculty of Medicine, Assuit university

Dean of NCI

Vice Dean of the College of Graduate Studies

Vice Dean of Education student affairs

Vice Dean of Environmental Affairs and Community Service

President of AMAAC

President of EHOG

President of KASO

President of Egyptian Cancer Society

President of ESLC

President of the Conference



12th

18

(Best oral presentation) Session10:00 12:00

Hall (A)

26th

FEBRUARY

FRIDAY


Prof. Abdel Motlib Mohamed Prof. Ahmed Elzawawy Prof. Hosna MostafaProf. Kamal ElghamrawyProf. Mostafa ElserafyProf. Omar Shebl

Prof. Omar ZakiProf. Salah Abdel MoniemProf. Salah ElmesidyProf. Sami ElkhatibProf. Samia abdel KarimProf. Samir Shehata

Moderator Prof. Hussien Khaled

10:00- 10:15 Head & Neck CancerAss. Lecturer :Ahmed Mostafa

10:15- 10:30 Case presentation GU ovarianAss. Lecturer :Nada Hassan

10:30- 10:45 HaematologyAss. Lecturer :Walaa Gamal

10:45- 11:00 Breast Ass. Lecturer :Heba Bakri

11:00- 11:15 BreastAss. Lecturer :Ahmed Hadeya

11:15- 11:30 Round table discussion

19

(Radiotherapy workshop) (Virtual)

13:00 18:15

Hall (A)

26th

FEBRUARY

FRIDAY


Prof. Ahmed El Sayed Prof. Ihab MostafaProf. Mohamed Wahman

Prof. Soha Abd El RazikProf. Somaya Ezzat

ModeratorsProf. Ahmed MarzokProf. Ashraf Farrag Prof. Mostafa El Hadad

13:00- 13:30 Role of radiotherapy in oligometastatic diseaseProf. Michael Eble (Germany)

13:30- 13:45 Flash RTH : A new hope to improve therapeutic ratio Prof. Kamal ElGhamrawy

13:45- 14:15 Cyber Knife : A technology recently serve in Egypt Prof. Mohamed Saad Zaghlol

14:15- 14:45 Radio therapeutic options in management of vulvar carcinomaProf. Mohamed Elsheikh (USA)

14:45- 15:15 MRI guided Rth for upper abdominal tumors advantages and limitationsProf. Tamer Refat (USA)

15:15- 15:45 Challenges and controversies in breast cancer radiation therapyProf. Fady Geara (Lebanon)

15:45- 16:15 Hypo fractionated breast RT :The less, The betterProf. Tarek Salah

16:15- 16:45 Re irradiation in Head and Neck cancerDr. Ahmed Allam

16:45- 17:15 RTH in era of Covid 19 : what is newProf. Belal Elhawary (Jordan)

17:15- 17:45 Recent advances in pediatric imagingProf. Hany Hafez

17:45- 18:15 Round table discussion



12th

20

26th

FEBRUARY

FRIDAY

Clinical Pharmacy Work Shop(Virtual)

10:0012:00

Hall (B)


Prof. Ekramy Abd ElRehim Prof. Dina FathallaProf. Mahmoud Shiha

Prof. Mohamed Abd El LatifDr. Ali Al Rumaih

ModeratorProf. Abdallah Abotaleb

10.00-10.20 Pharmacist rules during pandemic eraDr . Fakhr Al Ayoubi

10.20-10.40 Pharmacists and COVID 19 vaccinesProf. Abdallah Abotaleb

10.40-11.00 Pharmacists and resources allocations in oncology fieldMs. Lynn Al Tayara

11.00-11.20 What should pharmacists know about cancer future therapiesProf. Ekramy Abd ElRehim

11.20-11.40 Management of mucositits in H&N cancer patientsClin. Ph. Ahmed El Sarrif

11.40-12.00 Introduction and management of neutropenia Clin. Ph. Toka Safwat Clin. Ph .Marwa Kamal

Round Table Discussion

21

CORRELATION BETWEEN CLINICAL OUTCOMES AND PROLIFERATIVE INDEX (Ki-67) IN PATIENTS

WITH CANCER CERVIX Dungersi SH1, Belal AM1, Hegazy NEE1, Abdallah DM2

1Alexandria Clinical Oncology Department, Faculty of Medicine, Alexandria University, 2Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Introduction

Cervical cancer still poses a major problem in regards to mortality in

developing countries and hence the need to develop novel biomarkers to

predict prognosis and response.

The objectives of this study were to assess the correlation between Ki-67

and clinic-pathologic outcomes as well as to determine the response to

treatment in relation to Ki-67 and TILS. Secondary objectives included to

determine the one year overall survival and progression free survival in

relation to Ki-67.

Patients and Methods

Thirty patients with cervical cancer being treated at the Alexandria

University Main Hospital, Clinical Oncology department were selected.

Clinico-pathologic data was retrieved from the patient files.

Ki-67 and TILS were analyzed from the patient blocks. Chi square test,

Pearson correlation and Kaplan-Meier method was used to study the

associations and correlations between Ki-67, TILS and clinic-pathologic

outcomes, survival and progression free survival.



12th

22

Results

Important clinical features of the studied group include median age of 51

(range 30-77y), FIGO stage ⅠⅠB, lymph node metastasis (66.7%),

squamous cell carcinoma (80%), adenocarcinoma (10%).

There was no significant association between clinic-pathologic outcomes

including parametrial invasion (P(MC)=0.908), vaginal infiltration

(P(MC)=0.251), lymph node metastasis (P(MC)=0.182), FIGO stage

(P(MC)=0.736), histology (P(MC)=0.269), tumor grade (P(MC)=0.216 ),

tumor size (P=0.353) and Ki-67.

Response to treatment in relation to Ki-67 was statistically not significant

(p=0.924).

TILS and response to treatment did not demonstrate significant association

(p=0.183).

One year overall survival and PFS in relation to Ki-67 was not statistically

significant (p=0.248, p=0.867).

Interestingly a significant low positive correlation was noted between Ki-

67 and TILS (Pearson Correlation=0.378, p=0.039)

Conclusion

Expression of Ki-67 in cervical cancer is of doubtful value in relation to

clinical outcomes.

Both Ki-67 and TILS was limited in predicting tumor response.

There seems to be no relationship between Ki-67 and OS and PFS.

Notably a low positive correlation between Ki-67 and TILS was observed.

23

Abstract:

Microparticles and PD1 Interplay in Multiple Myeloma and Treatment Outcomes, Non Randomized Controlled Study

Asmaa M. Zahran1, Amal Rayan2

1Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.

2Clinical Oncology Department, Faculty of medicine, Assiut University, Assiut, Egypt.

Correspondence to: Amal Rayan

E-mail: [email protected]

Postal address: 71515, Assiut university hospital

ORCID iD: 0000-0001-5995-9177

Abstract topic: active multiple myeloma

Abstract structure:

Background:

Although multiple myeloma (MM) is still considered as an incurable disease by current

standards, the development of several combination therapies, and immunotherapy

approaches has raised the hope towards transforming MM into an indolent, chronic

disease, and possibly achieving a cure.

Objectives:

We tried to shed light on the expression of PD1 and different Microparticles (MPs)

in MM and their interplay as a mechanism of resistance to standardized treatments,

in addition, find their associations with prognostic factors of MM.



12th

24

Methods:

thirty patients with newly diagnosed and chemotherapy naïve active MM, along

with 20 healthy participants of comparable age and sex were recruited, after

diagnosis of MM; blood samples were collected from both patients and controls for

flow cytometric detection of CD4+, CD8+, CD4+PD1+, and CD8+PD1+ T cells,

total MPs, CD138+ MPs, and platelet MPs.

Results:

MM patients had statistically significant higher levels of TMPs, CD138+M compared to

their controls, while PMPs exhibited no significant difference between both groups.

Statistically significant higher percentages of CD8+T cells, PD1+CD8+, PD1+CD4+T cells

were detected in patients compared to controls, while the latter group had a significantly

higher percentage of CD4+T cells than MM patients, patients who didn't achieve complete

response, had significantly higher percentages of PMPs, CD138+MPs, PD1+CD8+,

PD1+CD4+, and CD8+T cells (cutoff values= 61, 10.6, 13.5, 11.3 & 20.1 respectively),

(p-values=0.002, 0.003, 0.017, 0.001 & 0.008 respectively).

Conclusion:

Microparticles and PD1 expressions were associated with proliferative potential and

resistance to Bortezomib-based treatments, our results suggested that they played a crucial

role in myeloma progression.

25

EVALUATION OF CHEMOTHERAPY SERVICE ATTHE

ALEXANDRIA UNIVERSITY CLINICAL ONCOLOGY

DEPARTMENT IN VIEW OF INTERNATIONAL

RECOMMENDATIONS

Regina NO1, Ashraf ME1, Sherif FE1 1Alexandria Clinical Oncology Department, Faculty of Medicine, Alexandria

University, Alexandria Egypt.

Introduction

Chemotherapy plays a major role in the current management of adult

oncology patients. The purpose of this study was to assess the aspects of

chemotherapy service in the clinical oncology department Alexandria

university hospital, to come up with recommendations and a chemotherapy

checklist to facilitate the chemotherapy process.

Patients and methods

This was a prospective observational study conducted on 300 new adult

patients seen from August 2019 to February 2020. Data were collected

from the prescription of the first cycle to the end of the chemotherapy

treatment. The patients’ demographic data, clinical details and

chemotherapy data were collected and analyzed using SPSS version 2.

Results.

The median age was 54 years old with a range of 17-83 years. 71.3% of

the patients were overweight or obese. Breast cancer accounted for 24.3%

of the cases, ovarian (6.7%) and colon/lung cancer (5.7%) each.



12th

26

Adriamycin/cyclophosphamide then Taxane was the most commonly used

regimen (16.7%), followed by Taxo/Carbo (12.3%) and Gem/cisplatin

(7%). Majority of the patients were on outpatient chemotherapy

(77%) and 23% were inpatients. A small percentage of patients (5%)

received target therapy. 82% of patients were on intravenous

chemotherapy and 6.3% on oral chemotherapy. 100% of the patients gave

verbal consent before the start of treatment. 21% of the patients had dose

modifications during their treatment cycle due to hematological toxicity

(29%), renal impairment (4%) or hepatic impairment (5%). The number of

chemotherapy cycles ranged between 3-8 cycles and the mean treatment

duration was 4 months. 4 out of 300 patients (1.3%) died before

completion of their treatment. 8.3% had neurological toxicity (72.2 %

grade 1&2, 27.8% grade 3) and 29% of patients developed hematological

toxicities (39.6% grade 1&2, 60.4 grade 3&4).5% of the patients had acute

gastrointestinal side effects. There was a statistical significant correlation

between the hematological toxicity and the treatment duration

(3.97 vs. 3.23), (p=0.002). Neurological toxicity also had a

significant correlation with the treatment duration (3.50 vs. 4.37),

(p=0.016). High BMI was correlated with increased incidence

of breast cancer, ovarian cancer, nasopharyngeal cancer,

esophageal cancer, Hepatocellular carcinoma and neuroendocrine

tumors.

Conclusion & recommendations

There is need to enhance support services for patients such as counseling

and nutritional advice. Provision of more targeted therapy is needed.

27

Written documented consent forms should be signed before chemotherapy.

Prompt management of hematological and neurological side effects will

lead to timely completion of the chemotherapy cycles. In addition, given

the current COVID 19 pandemic less intravenous chemotherapy, more oral

prescriptions, less inpatient treatments, use of 3 weekly regimen instead of

weekly and adequate social distancing are mandatory measures to reduce

exposure of our immunocompromised patients during the hospital visits.



12th

28

PRIMARY PEDIATRIC MALIGNANT BONE TUMORS;

A 10-YEAR OUTCOME.

Noordin BS1, Shady HF1, Bassma ME1, Alaa EK1

Alexandria Clinical oncology Department, Faculty of Medicine, Alexandria University.

INTRODUCTION

Primary pediatric bone tumors are very rare neoplasms and account for

approximately 6% of all childhood cancers. Osteosarcoma and The Ewing

sarcoma family of tumors are the two most common pediatric bone

malignancies accounting for 56% and 34% respectively. Others such as

chondrosarcoma (6%) are rarely seen in skeletally immature patients.

AIM OF THE WORK;

To evaluate treatment out-comes and prognostic factors in patient with

primary pediatric malignancies treated at Alexandria clinical oncology

department, in Alexandria university Hospital and Borg El-Arab university

Hospital in Egypt.

METHODOLOGY; This was a retrospective study, one hundred and fifty-four cases from January 2010 to

2019 December were retrieved from Files, clinical characteristic and treatment

outcomes were recorded.

RESULT Osteosarcoma accounted for majority of the cases 50% (n=77) followed by

Ewing sarcoma 48.7% (n=75) and the least common was chondrosarcoma

29

1.3% (n=2). Both osteosarcoma and Ewing’s sarcoma had a slight male

predominance, 57.1% (n=44) and 61.3% (n=46) respectively. Pain was the

most common presenting symptom in both tumors.

The 5-year overall survival for both localized and metastatic

osteosarcoma was 63.2%. Patient who presented with localized

osteosarcoma had 5-year overall survival of 75.8% while those who

presented metastatic disease had 5-year overall survival of 38.2%, this was

statistically significant with p-value of 0.016. The most common site for

metastasis was lungs, accounting for 65.71% (n=23) of the metastatic sites,

followed by spread to other bones 22.86%(n=8).

Patient with Ewing sarcoma, both with metastatic and non-

metastatic disease had a 5-year overall survival of 61.2%. Those

who presented with localized disease had 5-year overall survival

of 71.7% while those with metastatic disease at presentation had

41.2%, the difference was statistically significant with p-value of

0.022. The most common site for metastasis was also lungs

accounting for 62.5% (n=20) of the metastatic sites.

CONCLUSION: Patients with pediatric bone malignancies treated at Alexandria clinical

oncology department, in Alexandria university Hospital and Borg El Arab

university hospital had similar demographics and treatment outcome as

patients in the developed world.



12th

30

COMPARISION OF 7TH AND 8TH EDITIONS AJCC/UICC TNM STAGING IN CORRELATION WITH

SURVIVAL AND TREATMENT GUIDELINES FOR NON-SMALL CELL LUNG CANCER.

Irura TW1, Zahra OS2, Sherif FE3, Ahmed B4

1Resident in Clinical Oncology and Nuclear Medicine, Faculty of Medicine University of Alexandria, Egypt.

2 Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine University of Alexandria, Egypt.

3 Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine University of Alexandria, Egypt.

4Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine University of Alexandria, Egypt.

BACKGROUND

Worldwide, lung cancer continues to be the leading cause of cancer-related

deaths, despite screening and treatment progress with the lowest 5yr

survival rates, under 20% in developed countries. In Egypt, lung cancer is

the most lethal malignancy. Most patients present with locally advanced or

metastatic disease.

NSCLC comprise of 85-90% of all newly diagnosed lung and bronchus

tumors. The American joint committee on cancer (AJCC)/International

Union for Cancer Control (UICC) Tumor, Node and Metastasis (TNM)

staging system for lung cancer has been revised from the 5th to the 8th

editions over the last two decades.

31

The TNM Staging system can separate survival outcomes between the

stage, it can give the prognosis of the patient and the clinician can decide

the treatment modalities.

This study sought to show the discriminatory ability of this new staging

system and compare it with the 7th in the Egyptian patient cohort.

AIM OF THE WORK

This work aims to:

1. Reviewing all demographic and clinic-pathological features of these patients

2. Evaluate the discriminatory ability of the revised 8th edition T category, M

category and the prognostic accuracy of the staging system and compare it

with the 7th edition staging system.

METHODS

In this retrospective population-based cohort, data on patient characteristics, tumor

characteristics, diagnostic tools used to reach a diagnosis and treatment modalities

administered has been collected from the archive of Alexandria Clinical Oncology

Department.

Then all the patients were classified within the 7th and 8th AJCC/TNM classification

and the treatment modalities and survival outcomes compared.



12th

32

RESULTS

• The study was conducted on (222) Non-small cell lung cancer patients

between 20 and 80 years.

• All the 222 patients were classified with both the AJCC TNM 7th edition and

then reclassified with the AJCC TNM 8th edition to enable the comparison.

• There were no chances made in the nodal(N) category between the 7th and

8th AJCC/TNM staging. Majority of the patients had N3 disease.

• 7th edition, involvement of the mediastinal pleura was classified as T3 disease

it has since been removed from the T classification in TNM 8th edition

• The changes effected were, the 7th edition T1a was divided into the 8th edition

T1a and T1b categories, T2a was divided into T2a and T2b categories, T3 category

was recategorized into T2, T3 and T4 groups.

• In the Metastatic (M) category 7th edition, the division of metastatic disease

into M1a and M1b demonstrates an important change in TNM 8th Edition,

intrathoracic metastasis retains the M1a designation, but the extra thoracic

metastasis group has been split into M1b (single extra thoracic metastasis in a single

distant organ) and M1c (multiple extra thoracic metastases in one or more distant

organs)

• The comparison of the two staging systems.

33

Overall survival

Age in years

<30years 30-39 40-49 50-59 60+

Gender

Male Female

Nodal staging

N0 N1 N2 N3

Invasion

Plueral invasion Vessel invasion none



12th

34

Relationship between overall survival

and age.

Relationship between overall survial and gender.

Relationship between overall survival and nodal staging.

Relationship between overall survival and plueral or vessel invasion.

Relationship between 7th Tumour stage and Overall survival.

35

Relationship between 8th Tumour stage and Overall survival.

Relationship between 7th stage and overall survival.



12th

36

Relationship between 8th stage and overall survival.

CONCLUSIONS

• We were able to show that the survival time decreases as the pathological stage progresses.

• There were no changes in the Nodal staging between the 7th and the 8th edition.

• The metastatic staging that was changed was also shown to have an impact on survival outcomes.

• The 8th edition was shown to be more discriminatory in showing this.

37

Phase III Concurrent chemo-radiotherapy of weekly

paclitaxel versus weekly carboplatin in locally advanced

head and neck unfit for cisplatin

Abd el motaleb Mohamed 1 , Ahmed Z. Elattar 1 , Ahmed Hassan 2 , Mona Salah 1

1-Clinical Oncology Department, Faculty of Medicine Zagazig University

2-1-Clinical Oncology Department , Faculty of Medicine Ain Shams University

[email protected]

INTRODUCTION

In Egypt, the head and neck cancers represented 17% of all malignant [1]. But in United

State ofAmerica the head and neck cancer about 3 to 5% of all cancers and about 90 %

was squamous cell carcinoma and the incidence of head and neck cancers in United States

was 40000 people per year [2]. Most of squamous cell carcinoma presented in locally

advanced stage and treated with chemoradiotherapy protocol [2]. Many trails and meta-

analysis confirm benefits of survival and organ preservation adding chemotherapy to

radiotherapy in different sequences especially concurrent chemo-radiotherapy

AIM:

This prospective randomized study aiming to comparing the efficacy and toxicities of

concurrent chemo radiotherapy of weekly Taxol versus weekly carboplatin in locally

advanced head and neck carcinoma unfit for cisplatin.



12th

38

PATIENT AND METHODS:

The patient divided in two arms, paclitaxel arm; 25patients treated by weekly paclitaxel

40mg /m2 with radiotherapy and carboplatin arm; 25 patients treated by weekly 150 mg

carboplatin with radiotherapy. The three-dimensional radiotherapy planned (3DCRT)

was 65 to 70 GY and 1.8 -2 GY /fraction, 5 fractions/week in 6-7 weeks.

RESULTS:

There was an insignificant 5-year disease free survival was 79.5% in carboplatin arm

versus 84.6% in paclitaxel arm and 5-year OS was an insignificant 76% in carboplatin

arm versus 72% in paclitaxel arm (p-value=0.646) . A 44% of both arms had overall

complete remission. A 16% of patients received carboplatin had grade III/IV mucositis.

Patients in paclitaxel arm had more grade II neuropathy (60%). A comparable rate of

neutropenia had occurred in both arms.

CONCLUSION:

Both arms of concurrent chemo radiotherapy had acceptable toxicities with good

quality of life response to treatment where 44% of both arms had complete

response (p-value=0.623). There was an insignificant 5-year disease free survival

was 79.5% in carboplatin arm versus 84.6% in paclitaxel arm and 5-year OS was

an insignificant 76% in carboplatin arm versus 72% in paclitaxel arm

(p-value=0.646) . A 44% of both arms had overall complete remission

39

Figure (1): Kaplan-Meier plot: (A) Disease Free Survival

(DFS); (B) Overall survival (OS).

Platinum

Golden

Silver

Others

OFFICIAL ORGANIZER: ARAB ORGANIZERS FOR CONFERENCE MANAGEMENTAddress : 14 Mohamed Mandour Rabaa El Adaweya St.,-Nasr CityTel.: 0222603653 Mobile : +20 100 222 3158 / +20 1068663434 / +20 1068666085E-mail address : [email protected] Website: www.araborganizers.org

Documents

Those we love don't go away They walk beside us every moment